Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Novavax, Inc. announced today that the enrollment of over 3,500 subjects in Mexico has been completed in Stage B of its pivotal 2009 H1N1 virus-like-particle (VLP) pandemic influenza vaccine study. With the 1,000 subjects already enrolled in Stage A of the trial, the enrollment in this pivotal trial is now complete with over 4,500 subjects.
The Centers for Disease Control and Prevention has awarded Abt Associates two new contracts to evaluate the effectiveness of the H1N1 vaccine among health care workers and children under the age of 18.
NanoViricides, Inc., reports that it has filed a “Universal Form S-3 Shelf Registration” with the Securities and Exchange Commission for the sale from time to time of up to $40 million of its securities. The Company recently became eligible to file a shelf registration to register its securities.
Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has closed a $12.5 million Series B financing, led by Care Capital of Princeton NJ. The funding will be used to advance the Company's lead product, an oral vaccine for Avian influenza, through Phase I clinical trials.
BioSante Pharmaceuticals, Inc. today announced that it has received commitments from two institutional investors to purchase $18 million of securities in a registered direct offering. The investors are Great Point Partners, LLC and Deerfield Management Company. BioSante expects to receive net proceeds of approximately $17.5 million after deducting placement agent fees and other offering expenses.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.
China Nepstar Chain Drugstore Ltd., the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2009.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza.
If the behavior of the seasonal form of the H1N1 influenza virus is any indication, scientists say that chances are good that most strains of the pandemic H1N1 flu virus will become resistant to Tamiflu, the main drug stockpiled for use against it.
BioSante Pharmaceuticals, Inc. today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies.
Normally, this is the peak period for the flu in the United States. But that just doesn't seem to be the case this year.
Canada's pharmaceutical products industry stands out for its strong growth during the 2008-09 recession. This sets it apart from other industries covered in the Winter 2010 edition of The Conference Board of Canada's Canadian Industrial Profile Service - chemicals, plastic and rubber products, non-metallic mineral products, and computer and electronic products, which will take at least a couple of years to return to pre-recession production, revenue and profit levels.
iBio, Inc. announced today that it has agreed in principle to license its technology, the iBioLaunch™ platform, and provide technology transfer services to G-Con, LLC, a private Texas company, and its affiliates, for the development and manufacture of plant-expressed influenza vaccines at a new facility being constructed in Bryan, Texas. The “GreenVax Project” will show proof of concept for a large-scale vaccine production facility using Nicotiana plants grown hydroponically in a contained environment.
"Let's say you're a public health official from the Centers for Disease Control, and you don't really know how much disease is going to be averted by vaccinating different fractions of the population," said Manski, the Board of Trustees Professor in Economics in the Weinberg College of Arts and Sciences. "Then how should you choose a policy? That's really what the paper tries to address."
4medica, the leading independent provider of Web-based connectivity between physicians and clinical laboratories, announced today that it will demonstrate the versatility of its Integrated Health Record (IHR™) solution at the 2010 Annual Healthcare Information and Management Systems Society (HIMSS) Interoperability Showcase at booth #233 in Hall C of the Georgia World Congress Center in Atlanta from March 1-3, 2010.
Families Fighting Flu (FFF) fully supports today's vote by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) to expand the current influenza vaccination recommendations to include all adults aged 19 to 49 years of age. Previous recommendations included all other age groups with the exception of this new adult population. This new recommendation will be implemented beginning with the 2010-2011 influenza season.
A Chilean hospital's early use of antiviral treatment in influenza patients and other aggressive measures helped reduce the number of severe H1N1 cases and related deaths. Those are the findings of a new study, now available online (http://www.journals.uchicago.edu/doi/abs/10.1086/650750), published in the March 15, 2010 issue of Clinical Infectious Diseases.
In the fight against emerging infectious diseases, The Galveston National Laboratory (GNL), one of two National Institutes of Health funded bio-containment laboratories in the United States, is benefiting from IBM software to ensure the optimal performance of all equipment functioning within its facility. The GNL, which is dedicated to the study and prevention of emerging infectious diseases, will use IBM Maximo Asset Management Software to help automate, manage and ensure the performance of its 3,000 operating assets in one of the world's most complex medical research environments.
The U.S. Food and Drug Administration (FDA) on Monday recommended that the H1N1 (swine flu) strain be added to next year's seasonal flu vaccine, "putting an end to separate shots deployed against the pandemic," Bloomberg reports. The FDA committee voted unanimously to make the H1N1 strain one of the three strains included in the shot, according to the news service. "The panel's recommendations are routinely adopted and used to guide vaccine manufacturers," Bloomberg writes (Randall, 2/22).
NanoViricides, Inc. has filed its quarterly report with the Securities and Exchange Commission yesterday in a timely fashion.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.